Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe
This article was originally published in The Pink Sheet Daily
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.
You may also be interested in...
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.
European Notebook: EMA Meetings Go (Somewhat) Public; Walgreens’ Global Reach; Scottish Independence?
The European Medicines Agency moves closer to U.S.-style advisory committee meetings in public; two national referendums next month could hit Scotland’s biotech industry and Switzerland’s health insurance sector.